These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 1438684)

  • 61. Californium-252 neutron curietherapy for advanced cervical cancer.
    Maruyama Y; Bell PR; Yoneda J; Van Nagell JR
    Oncology; 1982; 39(4):209-15. PubMed ID: 7088471
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Interstitial 252Cf neutron therapy for glioblastoma multiforme.
    Maruyama Y; Chin HW; Young AB; Bean J; Tibbs P; Beach JL
    Am J Clin Oncol; 1982 Dec; 5(6):589-91. PubMed ID: 6299091
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Neutron interstitial brachytherapy for malignant gliomas: a pilot study.
    Patchell RA; Maruyama Y; Tibbs PA; Beach JL; Kryscio RJ; Young AB
    J Neurosurg; 1988 Jan; 68(1):67-72. PubMed ID: 2826722
    [TBL] [Abstract][Full Text] [Related]  

  • 64. In vitro determination of toxicity, binding, retention, subcellular distribution and biological efficacy of the boron neutron capture agent DAC-1.
    Tilly N; Olsson P; Hartman T; Coderre J; Makar M; Malmquist J; Sjöberg S; Pettersson J; Carlsson J; Glimelius B
    Radiother Oncol; 1996 Jan; 38(1):41-50. PubMed ID: 8850425
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Work in progress: 252Cf neutron brachytherapy for hemispheric malignant glioma.
    Maruyama Y; Chin HW; Young AB; Beach JL; Bean J; Tibbs P
    Radiology; 1982 Oct; 145(1):171-4. PubMed ID: 6289375
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Development of high-activity 252Cf sources for neutron brachytherapy.
    Martin RC; Laxson RR; Miller JH; Wierzbicki JG; Rivard MJ; Marsh DL
    Appl Radiat Isot; 1997; 48(10-12):1567-70. PubMed ID: 9463877
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Production, distribution and applications of californium-252 neutron sources.
    Martin RC; Knauer JB; Balo PA
    Appl Radiat Isot; 2000; 53(4-5):785-92. PubMed ID: 11003521
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Role of gel dosimeters in boron neutron capture therapy.
    Khajeali A; Farajollahi AR; Khodadadi R; Kasesaz Y; Khalili A
    Appl Radiat Isot; 2015 Sep; 103():72-81. PubMed ID: 26070173
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical trial of 252Cf neutron brachytherapy vs. conventional radiotherapy for advanced cervical cancer.
    Maruyama Y; Kryscio R; Van Nagell JR; Yoneda J; Donaldson E; Hanson M; Beach JL; Feola JM; Martin A; Parker C
    Int J Radiat Oncol Biol Phys; 1985 Aug; 11(8):1475-82. PubMed ID: 4019271
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Assessment of neutron/gamma-ray dose ratios in intracavitary 252Cf neutron therapy.
    Tai DL; Maruyama Y
    Radiology; 1978 Sep; 128(3):795-7. PubMed ID: 674658
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Immediate results of neutron contact therapy with 252Cf].
    Vtiurin BM; Zherbin EA; Kalinina NP; Galantseva GF; Medvedev VS
    Med Radiol (Mosk); 1979 Nov; 24(11):30-5. PubMed ID: 502779
    [No Abstract]   [Full Text] [Related]  

  • 72. Dose enhancement in fast neutron tumour therapy due to neutron captures in 10B.
    Carlsson J; Hartman T; Grusell E
    Acta Oncol; 1994; 33(3):315-22. PubMed ID: 8018361
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Californium-252 interstitial implants in carcinoma of the tongue.
    Vtyurin BM; Ivanov VN; Medvedev VS; Galantseva GF; Abdulkadyrov SA; Ivanova LF; Petrovskaya GA; Plichko VI
    Int J Radiat Oncol Biol Phys; 1985 Mar; 11(3):441-9. PubMed ID: 3972658
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Manifestations of the "tumor bed" effect on exposure to 252Cf gamma-neutron irradiation and to 60Co gamma rays].
    Kurpeshev OK; Konopliannikov AG
    Med Radiol (Mosk); 1977 Oct; 22(10):83-4. PubMed ID: 916849
    [No Abstract]   [Full Text] [Related]  

  • 75. [The CT-stereotaxic neutron brachytherapy of brain tumors with californium sources on the ANET-B apparatus].
    Melikian AG; Liass FM; Shkol'nik FG; Chekhonadskiĭ VN; Elisiutin GP; Golanov AV; Kachkov IA; Borodkin SM; Lobanov SA; Spasokukotskaia ON
    Zh Vopr Neirokhir Im N N Burdenko; 1992; (2-3):15-21. PubMed ID: 1326193
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Neutron capture autoradiographic study of the biodistribution of 10B in tumor-bearing mice.
    Ogura K; Yanagie H; Eriguchi M; Lehmann EH; Kühne G; Bayon G; Kobayashi H
    Appl Radiat Isot; 2004 Oct; 61(4):585-90. PubMed ID: 15246403
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical study of relative biological effectiveness for cervical carcinoma treated by 252Cf neutrons and assessed by histological tumour eradication.
    Maruyama Y; Feola JM; Wierzbicki J; van Nagell JR; Powell D; Yoneda J
    Br J Radiol; 1990 Apr; 63(748):270-7. PubMed ID: 2112036
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Rapid clearance of advanced pelvic carcinomas by low dose rate 252Cf neutron therapy.
    Maruyama Y
    Radiology; 1979 Nov; 133(2):473-5. PubMed ID: 493540
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy.
    Hartman T; Carlsson J
    Radiother Oncol; 1994 Apr; 31(1):61-75. PubMed ID: 8041899
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Reduction of the gamma-ray component from 252Cf fission neutron source--optimization for biological irradiations and comparison with MCNP code.
    Endo S; Stevens DL; Bonner P; Hill MA; Nikjoo H; Dalla Vecchia M; Komatsu K; Hoshi M; Goodhead DT
    Phys Med Biol; 1999 May; 44(5):1207-18. PubMed ID: 10368013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.